Indications
Calcium carbonate, chemically CaCO3, is a resonance-stabilized inorganic salt therapeutically used as a food additive, a dietary supplement, an antacid, and a phosphate binder. Calcium carbonate is among the most abundant compounds found in the earth's crust and is commonly found in organic substances, such as egg and oyster shells, crustaceans exoskeletons, and dark leafy greens, such as broccoli and kale.[1] Calcium carbonate uses extend beyond medicine. Calcium carbonate has industrial uses as filler in paint, paper, fire extinguishers, and adhesives, as a component of agricultural and mining dust, as an ingredient in household cleaners, as a food coloring compound, and as an ingredient in cosmetics.[1]
In pharmaceuticals, calcium carbonate is a food additive used for nutritional benefits, is a calcium supplement used to treat low serum calcium conditions, is an antacid for gastrointestinal ailments, is a phosphate binder for chronic kidney disease, and is a tableting excipient used in the making of other pharmaceutical agents and foodstuffs.[1][2]
Calcium carbonate is indicated for low serum calcium conditions, such as osteoporosis, osteomalacia, hypothyroidism, hypoparathyroidism, pseudohypoparathyroidism, DiGeorge syndrome, kidney dysfunction, pancreatitis, rheumatoid arthritis, Fanconi syndrome, pregnancy, nursing mothers, post-menopausal women, and while using certain medications.[3][4][5][6][7] The medications that require concurrent calcium supplement use include:
- Rifampin (antibiotic)
- Loop-diuretics
- Anti-seizure medications (phenytoin and phenobarbital)
- Bisphosphonates (alendronate, ibandronate, zoledronic acid, and risedronate)
- Calcitonin
- Chloroquine
- Corticosteroids
- Plicamycin
- Citrate use during apheresis (anticoagulant) [8][9][10]
As an antacid, calcium carbonate is indicated for heartburn caused by gastroesophageal reflux disease (GERD), NSAID upper gastrointestinal mucosal damage, duodenal and gastric ulcers, biliary reflux, stress gastritis exocrine pancreatic insufficiency, bile acid-mediated diarrhea, Non-ulcer dyspepsia, and urinary alkalization.[11][12][13] Like aluminum and magnesium salts, calcium carbonate increases gut motility and has indications for constipation treatment.[14]
Calcium carbonate is also indicated for use in treating hyperphosphatemia seen in chronic kidney disease, as a phosphate binder, as a way of treating overdose by causing urinary alkalization, and as a prophylactic treatment in pregnant patients before birth to prevent aspiration pneumonitis.[15][16]
New research suggests that the indications for calcium carbonate may also include cancer treatment by using calcium supplements to treat colorectal adenomas and using rare-earth-doped calcium carbonate with cerium to kill tumor cells via X-ray-induced photodynamic therapy.[17][18]
Mechanism of Action
Register For Free And Read The Full Article
- Search engine and full access to all medical articles
- 10 free questions in your specialty
- Free CME/CE Activities
- Free daily question in your email
- Save favorite articles to your dashboard
- Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Mechanism of Action
Calcium is naturally present in the body. Most of the body's stored calcium is within the bones and teeth as hydroxyapatite. The rest of the body's calcium is in blood, extracellular fluid, muscle, and other body tissues.[19] In the blood, 40% of calcium is bound to albumin, 13% binds to an anion, like phosphate and lactate, and the majority, 47%, is free, unbound, ionized calcium (Ca2+). The amount of ionized calcium found in the blood is essential and tightly regulated by homeostatic controls because it is physiologically active and plays a vital role in the cellular processes of excitable tissues, such as blood vessels, muscles, glands, and nerves.[1]
Calcium carbonate has three separate mechanisms of action that have pharmacologic effects. Calcium affects the stomach, small intestine, and blood.[20]
As an antacid, calcium carbonate neutralizes gastric acid by acting as a buffer in the stomach's acidic environment. When CaCO3 enters the stomach, it dissociates into ionized calcium (Ca2+) and a carbonate anion (CO32-). The carbonate anion will then bind to the free protons (H+) found in the stomach to increase the pH by decreasing the concentration of hydrogen ions. By increasing the pH in the stomach, pepsin, bile acids, and the toxins of Helicobacter pylori become inhibited.[21]
The inhibition of pepsin, an enzyme that can degrade tissue protein, and inhibition of bile acid helps reduce damage to and promote the healing of ulcers in the mucosal lining of the stomach and duodenum and injury to the esophagus caused by GERD.[21] There is still some criticism regarding the ulcer-healing effects of calcium carbonate solely being due to its acid-neutralizing mechanism because calcium carbonate can cause acid rebound by increasing plasma gastrin levels and has been shown to increase prostaglandins PGE2 and PGF2 after long-term use that may explain an alternative mechanism to ulcer healing.[22][23][24]
As an antacid, calcium carbonate also increases gastrointestinal motility and initiates peristalsis.[14][25] When the calcium carbonate is chewed and partially digested, the free calcium stimulates peristalsis in the esophagus to move the acid into the stomach and decrease heartburn symptoms.[25]
Calcium carbonate works in the small intestines as a phosphate binder and drug chelator. In individuals with hyperphosphatemia or overdose, calcium will bind to form an insoluble compound blocking dietary phosphate or excess drug absorption and excreting it in feces. Additionally, calcium carbonate, used as a calcium supplement, also acts in the small intestine by chelating with oxalate to prevent absorption and renal calculi formation.[1]
Lastly, calcium carbonate also works in the blood to treat or prevent negative calcium balance seen in low serum calcium conditions.[1] After being absorbed in the small intestines actively with the help of vitamin D and passively vi-a diffusion, ionized calcium circulates in the blood.
Pharmacokinetics
Absorption: After ingesting calcium carbonate tablets, they are broken down in the stomach to form soluble calcium salts. As a result, calcium becomes available for absorption in the body. Calcium absorption occurs in the small intestine by active transport dependent on Vitamin D and diffusion. Fractional calcium absorption, the amount of calcium absorbed over the amount ingested, changes throughout life and is highest in infancy, early puberty, and the last two trimesters of pregnancy for women. It steadily declines as an individual progresses into old age, with a marked decrease starting after menopause for women and late '50s for men.[19] Besides age and the form of calcium carbonate, calcium absorption can be affected by the dose given, stomach pH, estrogen status, vitamin D level, and genetic polymorphisms.[11]
The fractional absorption is highest at 500 mg when taken with food, and the stomach is acidic. Fractional absorption also increases when the person has sufficient vitamin D, does not have an absorption disorder, is young, has more estrogen, and has a larger body size.[26] Absorption of calcium carbonate decreases if an individual has a mucosal lining disorder or achlorhydria.[27]
Distribution: As previously mentioned, calcium storage in the body is primarily in bones and teeth. However, most of the calcium is found in the ionized, physiologically active form in the blood.
Elimination: Calcium carbonate is excreted in the feces as unabsorbed calcium carbonate, in the urine depending on glomerular filtration and renal tubule reabsorption controlled by parathyroid hormone (PTH) and Vitamin D, and as carbon dioxide from the lungs.[1]
Administration
Calcium carbonate comes in tablet, chewable, oral suspension, or powder form. Tablets should be swallowed while drinking a full glass of water. The oral suspension should be well shaken before measuring the dose to ensure the ingestion of the proper amount. The bioavailability of calcium from calcium carbonate is higher as a powder.[28] Although calcium citrate has a higher bioavailability of calcium than calcium carbonate, in foods fortified with calcium, calcium carbonate allows for better absorption than other calcium-fortification compounds.[1][29] 1000 mg of calcium carbonate is equivalent to 400 mg of elemental calcium.
- Dosing depends on the indicated condition and the patient's age. For adult use for heartburn, dosing ranges from 500 mg to 1000 mg and should not exceed 7 grams daily.
- RDI of Calcium for adults is 1 to 1.2 gm daily, and for post-menopausal women, 1.2 gm preferably from dietary sources. For calcium supplementation, 500 mg to 4 grams of calcium carbonate may be taken orally daily, divided, and with meals.
- For adults with hyperphosphatemia, 1.5 to 3 grams per day effectively achieves optimal phosphate control in 65% of patients.[30]
If the patient misses a regular dose, they should take it when they remember it unless it is close to the next dose. At the time of the next dose, they should take the regular dose and not double it.
Beyond age and form of calcium carbonate, calcium absorption can be affected by the dose given, stomach pH, patient size, estrogen status, vitamin D level, and genetic polymorphisms.[1][11] When taken with food, the fractional absorption is highest at 500 mg, and the stomach is acidic. Fractional absorption also increases when the person has sufficient vitamin D, does not have an absorption disorder, is young, has more estrogen, and has a larger body size.[31] Absorption of calcium carbonate decreases if an individual has a mucosal lining disorder or achlorhydria.[27]
Specific Patient Populations
Hepatic Impairment: The product labeling for calcium carbonate does not include any dosage adjustments for hepatic impairment.
Renal Impairment: As per the KDIGO guidelines for Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD), it is recommended to monitor serum levels of calcium, phosphate, parathyroid hormone, and alkaline phosphatase beginning in CKD G3a (eGFR: 45-59 mL/min/1.73 m²) for adults and in CKD G2 (eGFR: 60-89 mL/min/1.73 m²) for children. For adults with CKD G3a((eGFR: 45 mL/min/1.73 m² or less)-G5D, the guidelines suggest avoiding hypercalcemia. Similarly, in children with CKD G3a-G5D, maintaining serum calcium within the age-appropriate normal range is advised. CKD G5D indicates End-Stage Renal Disease (ESRD), where the eGFR is 15 mL/min/1.73 m² or less and typically necessitates renal replacement therapy, such as dialysis or kidney transplantation.
Pregnancy Considerations: Calcium carbonate is for aspiration prophylaxis before labor.[2][12] GERD occurs in up to 80% of pregnant women by the end of the third trimester. According to the American College of Gastroenterology (ACG) guidelines, treatment typically starts with lifestyle adjustments. Antacids, including calcium carbonate, are the first-line options if these don't suffice. Calcium carbonate is considered safe, effectively neutralizes stomach acid, and provides relief from heartburn and acid indigestion without significant risk to the fetus. However, at high doses, antacids containing calcium can cause milk-alkali syndrome.[32]
Breastfeeding Considerations: Calcium can travel through the placenta and into breast milk during nursing. However, it is unlikely that the additional intake of these minerals by a nursing mother will exceed what is found in other infant foods. Considering these factors, experts generally deem antacids such as calcium carbonate used during breastfeeding acceptable. No specific precautions are necessary in this regard.[33]
Adverse Effects
Due to the short-term, periodic nature of calcium carbonate/antacid use and the small dose of calcium carbonate used for supplementation, most adverse effects are minor. However, an overdose can occur if large doses are taken for an extended time or abused. The patient can experience moderate to severe side effects of an overdose.[34] These include:
- Coma
- Confusion
- Irregular heart rhythms
- Muscle twitching
- Bone pain
- Abdominal pain
- Pancreatitis[35][35]
- Acute renal failure
- Kidney stones[36]
- Headache
- Milk-alkali syndrome[37]
- Gall stones[38]
Milk-alkali syndrome was historically a much more common severe side effect. Milk-alkali syndrome results from hypercalciuria and alkaluria, predisposing renal calculi and causing sequelae such as pancreatitis and acute renal failure.[39]
Common Adverse Effects:
- High calcium levels
- Low phosphate levels
- Vomiting
- Nausea
- Constipation
- Gas
- Loss of appetite or anorexia
- Irritability
- Xerostomia
- Acid rebound [2]
Additional adverse effects occur in individuals taking calcium carbonate as a phosphate binder to treat hyperphosphatemia, including calcification of vascular tissues and death.[30]
Drug-Drug Interactions
Calcium carbonate should be stored at room temperature and not frozen or exposed to heat.[12] Calcium carbonate should not be administered with other drugs known to decrease its absorption, such as histamine-2 receptor antagonists, glucocorticoids, and thiazide diuretics, but rather rescheduled to be taken at separate times.[1][40] Conversely, vitamin D will increase the absorption of calcium carbonate if coadministered, and patients are encouraged to take it together.[1][26]
Additionally, calcium carbonate will limit many drugs' effectiveness if taken together by increasing stomach pH and decreasing absorption.[11] These drugs include bisphosphonates, fluoroquinolones, tetracyclines, thyroid hormones, proton pump inhibitors such as omeprazole, iron, and anti-arrhythmic drugs like verapamil.[1][11][41] Calcium carbonate can also interact with the excretion of many drugs as it causes urine alkalization and will quicken the excretion of drugs that exist as weak acids and lengthen the excretion of drugs that exist as weak bases in the blood.[11]
Contraindications
Calcium carbonate use is contraindicated in hypersensitivity, renal calculus, high urine calcium levels, elevated serum calcium, low serum phosphate, achlorhydria, or suspected digoxin toxicity.
Care is necessary for patients with a history of kidney disease, heart failure, edema, or endocrine disorders, such as hypoparathyroidism.[42][43] Additionally, calcium carbonate users should never be prescribed ceftriaxone as an antibiotic because of the increased risk of end-organ failure and death.[44]
Monitoring
Adult patients using calcium carbonate as a supplemental therapy should have their serum phosphate and calcium levels periodically monitored to prevent adverse reactions and electrolyte imbalances. If patients continually return to using calcium carbonate, their symptoms require investigation to determine the root cause. Importantly, any patients using calcium carbonate for any reason should never be prescribed ceftriaxone to prevent end-organ failure.[44]
Administration of calcium carbonate should be separated from the administration of all medications that have drug interactions mentioned above, apart from vitamin D. Patients with hyperphosphatemia should have their serum calcium routinely monitored to prevent hypercalcemia and other sequelae, including myocardial infarction, vascular calcification, and death.
Pediatric and older patients should be routinely monitored if using calcium carbonate and advised against long-term use.
Toxicity
The FDA recognizes calcium carbonate as a generally safe drug and food additive.[1] A maximum dose of 8 to 10 g per day of calcium carbonate can be administered for short-term use.[2][45] However, long-term use of over 2 grams can lead to adverse effects such as hypercalcemia, renal calculi, hypophosphatemia, and nephrotoxicity, especially in individuals with chronic kidney disease.[1][11] Fetotoxicity has also been observed in pregnant women taking over 1500 mg/kg of body weight per day of calcium carbonate.[1]
Enhancing Healthcare Team Outcomes
As a non-prescription drug, calcium carbonate is easily accessible "over the counter" and often used. Proper patient education by clinicians and pharmacists is needed to avoid improper use. Symptomatic relief provided by calcium carbonate often masks underlying gastrointestinal disorders that will not improve by using the drug. Patient awareness is necessary to hasten the correct diagnosis and treatment. Furthermore, patients on polypharmacy need to understand calcium carbonate's drug interactions. Clinicians should advise their patients to take their medications at separate times of the day and limit additional calcium intake that could lead to overdose and milk-alkali syndrome. Working with a pharmacist to assist with medication reconciliation would be a prudent choice to prevent adverse drug-drug interactions. Nurses can also work with the patient to answer questions, review appropriate dosing, and ensure patient compliance. These are examples of how interprofessional teamwork and communication can improve patient results with calcium carbonate therapy, respective of the reason the patient takes it.
Proper clinician education on considerations when prescribing, monitoring, and stopping treatment is also necessary. Vigilance is essential, and routine monitoring should occur when prescribing calcium carbonate to patients with hyperphosphatemia due to the possibility of calcification of vascular tissues. Care is also necessary when prescribing calcium carbonate to infants and older patients because of renal function changes. Additionally, calcium carbonate should not be coadministered with ceftriaxone because of an increased risk of end-organ failure.
All interprofessional healthcare team members can improve outcomes by ensuring patient compliance. Patient compliance is problematic with calcium carbonate because of its interactions, adverse effects, and frequency of administration. Calcium carbonate can be inconvenient because it must be taken alone, except for vitamin D and other drugs that do not require a low stomach pH. Calcium carbonate has many gastrointestinal side effects, especially for older adults. Calcium carbonate prescriptions can also translate to a high pill burden, like patients with hyperphosphatemia who may require more than 17 doses daily. Encouraging patient compliance and proper scheduling would greatly help improve patients on polypharmacy, those with comorbidities, and those who need to limit dietary electrolytes.
References
Al Omari MM, Rashid IS, Qinna NA, Jaber AM, Badwan AA. Calcium Carbonate. Profiles of drug substances, excipients, and related methodology. 2016:41():31-132. doi: 10.1016/bs.podrm.2015.11.003. Epub 2016 Feb 3 [PubMed PMID: 26940168]
Level 2 (mid-level) evidenceSalisbury BH, Terrell JM. Antacids. StatPearls. 2023 Jan:(): [PubMed PMID: 30252305]
Karatzas A, Paridis D, Kozyrakis D, Tzortzis V, Samarinas M, Dailiana Z, Karachalios T. Fanconi syndrome in the adulthood. The role of early diagnosis and treatment. Journal of musculoskeletal & neuronal interactions. 2017 Dec 1:17(4):303-306 [PubMed PMID: 29199190]
Bilezikian JP, Brandi ML, Cusano NE, Mannstadt M, Rejnmark L, Rizzoli R, Rubin MR, Winer KK, Liberman UA, Potts JT Jr. Management of Hypoparathyroidism: Present and Future. The Journal of clinical endocrinology and metabolism. 2016 Jun:101(6):2313-24. doi: 10.1210/jc.2015-3910. Epub 2016 Mar 3 [PubMed PMID: 26938200]
Jorde R, Szumlas K, Haug E, Sundsfjord J. The effects of calcium supplementation to patients with primary hyperparathyroidism and a low calcium intake. European journal of nutrition. 2002 Dec:41(6):258-63 [PubMed PMID: 12474069]
Level 1 (high-level) evidenceNakamura Y, Suzuki T, Yoshida T, Yamazaki H, Kato H. Vitamin D and Calcium Are Required during Denosumab Treatment in Osteoporosis with Rheumatoid Arthritis. Nutrients. 2017 Apr 26:9(5):. doi: 10.3390/nu9050428. Epub 2017 Apr 26 [PubMed PMID: 28445420]
Scott DL, Farr M, Hawkins CF, Wilkinson R, Bold AM. Serum calcium levels in rheumatoid arthritis. Annals of the rheumatic diseases. 1981 Dec:40(6):580-3 [PubMed PMID: 7332378]
Lim LS, Fink HA, Blackwell T, Taylor BC, Ensrud KE. Loop diuretic use and rates of hip bone loss and risk of falls and fractures in older women. Journal of the American Geriatrics Society. 2009 May:57(5):855-62. doi: 10.1111/j.1532-5415.2009.02195.x. Epub 2009 Apr 2 [PubMed PMID: 19368583]
Lee G, Arepally GM. Anticoagulation techniques in apheresis: from heparin to citrate and beyond. Journal of clinical apheresis. 2012:27(3):117-25. doi: 10.1002/jca.21222. Epub 2012 Apr 24 [PubMed PMID: 22532037]
Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial. Annals of internal medicine. 1996 Dec 15:125(12):961-8 [PubMed PMID: 8967706]
Level 1 (high-level) evidenceMaton PN, Burton ME. Antacids revisited: a review of their clinical pharmacology and recommended therapeutic use. Drugs. 1999 Jun:57(6):855-70 [PubMed PMID: 10400401]
Dağlı Ü, Kalkan İH. Treatment of reflux disease during pregnancy and lactation. The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology. 2017 Dec:28(Suppl 1):S53-S56. doi: 10.5152/tjg.2017.14. Epub [PubMed PMID: 29199169]
Ching CK, Lam SK. Antacids. Indications and limitations. Drugs. 1994 Feb:47(2):305-17 [PubMed PMID: 7512903]
Matzkies F, Köhler M, Webs B. [The effect of 4 different antacids on the gastrointestinal tract and mineral metabolism]. Fortschritte der Medizin. 1984 Jun 28:102(24):661-5 [PubMed PMID: 6469178]
Level 1 (high-level) evidenceMeyer C, Cameron K, Battistella M. New agent to treat elevated phosphate levels: magnesium carbonate/calcium carbonate tablets. CANNT journal = Journal ACITN. 2012 Oct-Dec:22(4):33-5; quiz 36-7 [PubMed PMID: 23413537]
Chan S, Au K, Francis RS, Mudge DW, Johnson DW, Pillans PI. Phosphate binders in patients with chronic kidney disease. Australian prescriber. 2017 Feb:40(1):10-14. doi: 10.18773/austprescr.2017.002. Epub 2017 Feb 1 [PubMed PMID: 28246429]
Yang CC, Wang WY, Lin FH, Hou CH. Rare-Earth-Doped Calcium Carbonate Exposed to X-ray Irradiation to Induce Reactive Oxygen Species for Tumor Treatment. International journal of molecular sciences. 2019 Mar 6:20(5):. doi: 10.3390/ijms20051148. Epub 2019 Mar 6 [PubMed PMID: 30845750]
Chu DZ, Hussey MA, Alberts DS, Meyskens FL Jr, Fenoglio-Preiser CM, Rivkin SE, Mills GM, Giguere JK, Blanke CD, Goodman GE. Colorectal Chemoprevention Pilot Study (SWOG-9041), randomized and placebo controlled: the importance of multiple luminal lesions. Clinical colorectal cancer. 2011 Dec:10(4):310-6. doi: 10.1016/j.clcc.2011.06.005. Epub 2011 Jul 22 [PubMed PMID: 21782524]
Level 3 (low-level) evidenceInstitute of Medicine (US) Standing Committee on the Scientific Evaluation of Dietary Reference Intakes. Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride. 1997:(): [PubMed PMID: 23115811]
Antonini R, Biandrate F, Piccolini M, Francia L. [Oncocytoma of the kidney: a diagnostic and therapeutic dilemma]. Minerva chirurgica. 1989 Oct 15:44(19):2113-8 [PubMed PMID: 2694016]
Level 3 (low-level) evidenceTarnawski A, Ahluwalia A, Jones MK. Gastric cytoprotection beyond prostaglandins: cellular and molecular mechanisms of gastroprotective and ulcer healing actions of antacids. Current pharmaceutical design. 2013:19(1):126-32 [PubMed PMID: 22950493]
Level 3 (low-level) evidenceWeberg R, Berstad K, Berstad A. Acute effects of antacids on gastric juice components in duodenal ulcer patients. European journal of clinical investigation. 1990 Oct:20(5):511-5 [PubMed PMID: 2124982]
Level 1 (high-level) evidenceHade JE, Spiro HM. Calcium and acid rebound: a reappraisal. Journal of clinical gastroenterology. 1992 Jul:15(1):37-44 [PubMed PMID: 1500660]
Level 1 (high-level) evidencePreclik G, Stange EF, Gerber K, Fetzer G, Horn H, Schneider A, Ditschuneit H. Effect of antacid treatment on endogenous prostaglandin synthesis in human antral and duodenal mucosa. Digestive diseases and sciences. 1989 Dec:34(12):1860-4 [PubMed PMID: 2598753]
Rodriguez-Stanley S, Ahmed T, Zubaidi S, Riley S, Akbarali HI, Mellow MH, Miner PB. Calcium carbonate antacids alter esophageal motility in heartburn sufferers. Digestive diseases and sciences. 2004 Nov-Dec:49(11-12):1862-7 [PubMed PMID: 15628717]
Sunyecz JA. The use of calcium and vitamin D in the management of osteoporosis. Therapeutics and clinical risk management. 2008 Aug:4(4):827-36 [PubMed PMID: 19209265]
Recker RR. Calcium absorption and achlorhydria. The New England journal of medicine. 1985 Jul 11:313(2):70-3 [PubMed PMID: 4000241]
Wang H, Bua P, Capodice J. A comparative study of calcium absorption following a single serving administration of calcium carbonate powder versus calcium citrate tablets in healthy premenopausal women. Food & nutrition research. 2014:58():. doi: 10.3402/fnr.v58.23229. Epub 2014 Apr 22 [PubMed PMID: 24772062]
Level 2 (mid-level) evidenceNicar MJ, Pak CY. Calcium bioavailability from calcium carbonate and calcium citrate. The Journal of clinical endocrinology and metabolism. 1985 Aug:61(2):391-3 [PubMed PMID: 4008614]
Shaman AM, Kowalski SR. Hyperphosphatemia Management in Patients with Chronic Kidney Disease. Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society. 2016 Jul:24(4):494-505. doi: 10.1016/j.jsps.2015.01.009. Epub 2015 Jan 12 [PubMed PMID: 27330380]
Harvey JA, Zobitz MM, Pak CY. Dose dependency of calcium absorption: a comparison of calcium carbonate and calcium citrate. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 1988 Jun:3(3):253-8 [PubMed PMID: 3213620]
Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ. ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. The American journal of gastroenterology. 2022 Jan 1:117(1):27-56. doi: 10.14309/ajg.0000000000001538. Epub [PubMed PMID: 34807007]
. Antacids. Drugs and Lactation Database (LactMed®). 2006:(): [PubMed PMID: 30000381]
Nykamp D, Kraus EJ. Antacid-induced acute pancreatitis. The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists. 2013 Apr:28(4):247-51. doi: 10.4140/TCP.n.2013.247. Epub [PubMed PMID: 23552706]
Level 3 (low-level) evidenceDaniel NJ, Wadman MC, Branecki CE. Milk-alkali-induced pancreatitis in a chronically hypocalcemic patient with DiGeorge syndrome. The Journal of emergency medicine. 2015 Mar:48(3):e63-6. doi: 10.1016/j.jemermed.2014.09.061. Epub 2014 Dec 12 [PubMed PMID: 25498850]
Level 3 (low-level) evidenceSorensen MD. Calcium intake and urinary stone disease. Translational andrology and urology. 2014 Sep:3(3):235-40. doi: 10.3978/j.issn.2223-4683.2014.06.05. Epub [PubMed PMID: 26816771]
Medarov BI. Milk-alkali syndrome. Mayo Clinic proceedings. 2009 Mar:84(3):261-7. doi: 10.1016/S0025-6196(11)61144-0. Epub [PubMed PMID: 19252114]
Yu JK, Pan H, Huang SM, Huang NL, Yao CC, Hsiao KM, Wu CW. Calcium content of different compositions of gallstones and pathogenesis of calcium carbonate gallstones. Asian journal of surgery. 2013 Jan:36(1):26-35. doi: 10.1016/j.asjsur.2012.06.001. Epub 2012 Jul 31 [PubMed PMID: 23270822]
Herzog P, Holtermüller KH. Antacid therapy--changes in mineral metabolism. Scandinavian journal of gastroenterology. Supplement. 1982:75():56-62 [PubMed PMID: 6293043]
Hatlebakk JG, Berstad A. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease. Clinical pharmacokinetics. 1996 Nov:31(5):386-406 [PubMed PMID: 9118586]
Cook JD, Dassenko SA, Whittaker P. Calcium supplementation: effect on iron absorption. The American journal of clinical nutrition. 1991 Jan:53(1):106-11 [PubMed PMID: 1984334]
Bolland MJ, Grey A, Reid IR. Calcium supplements and cardiovascular risk: 5 years on. Therapeutic advances in drug safety. 2013 Oct:4(5):199-210. doi: 10.1177/2042098613499790. Epub [PubMed PMID: 25114781]
Level 3 (low-level) evidenceHill Gallant KM, Spiegel DM. Calcium Balance in Chronic Kidney Disease. Current osteoporosis reports. 2017 Jun:15(3):214-221. doi: 10.1007/s11914-017-0368-x. Epub [PubMed PMID: 28474258]
Steadman E, Raisch DW, Bennett CL, Esterly JS, Becker T, Postelnick M, McKoy JM, Trifilio S, Yarnold PR, Scheetz MH. Evaluation of a potential clinical interaction between ceftriaxone and calcium. Antimicrobial agents and chemotherapy. 2010 Apr:54(4):1534-40. doi: 10.1128/AAC.01111-09. Epub 2010 Jan 19 [PubMed PMID: 20086152]
Camidge R, Peaston R. Recommended dose antacids and severe hypercalcaemia. British journal of clinical pharmacology. 2001 Sep:52(3):341-2 [PubMed PMID: 11560570]
Level 3 (low-level) evidence